Allergic conjunctivitis

Disease ID:1193
Name:Allergic conjunctivitis
Associated with:0 targets
0 immuno-relevant targets
8 immuno-relevant ligands
Chronic inflammation of the conjunctiva involing red, itchy, and watery eyes caused by exposure to an allergen or irritant.
Database Links
Disease Ontology: DOID:11204


No target related data available for Allergic conjunctivitis


Ligand Approved Immuno References Clinical comments
olopatadine  [  ( ]
Clinical Use: Olopatadine is contained in opthalmic solutions used to treat the symptoms of seasonal allergic conjunctivitis, including itching, redness and swelling.
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
lodoxamide  [  ( ]
Clinical Use: Lodoxamide is used in opthalmic solutions to treat occular inflammation (keratitis or conjunctivitis) caused by the allergic response.
Immuno Disease Comments: Approved drug for allergic (non-infectious) occular inflammation.
fluorometholone  [  ( ]
Clinical Use: Fluorometholone is used to treat inflammatory conjunctivitis.
Immuno Disease Comments: A topically applied corticosteroid used to treat inflammatory conjunctivitis.
loteprednol etabonate  [  ( ]
Clinical Use: Used to treat eye swelling caused by surgery, infection, allergies, and other conditions.
Immuno Disease Comments: A corticosteroid used to treat ocular inflammation.
diphenylpyraline  [  ( ]
Clinical Use: Diphenylpyraline is an antihistamine used to treat allergic rhinitis, hay fever, and allergic skin disorders. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation.
Immuno Disease Comments: Antihistamine approved for allergic conjunctivitis
alcaftadine  [  ( ]
Clinical Use: Used in an opthalmic solution to treat the symptoms of allergic conjunctivitis.
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
cromoglicic acid  [  ( ]
Clinical Use: Cromoglicic acid is available in different formulations; nasal spray is used to treat allergic rhinitis, nebulizer solution to treat asthma, eye drops to treat allergic conjunctivitis and an oral form to treat mastocytosis,dermatographic urticaria and ulcerative colitis.
Recent reports suggest that cromolyn inhibits glycogen synthase kinase 3β and may therefore have potential to treat diabetes and obesity [1] and may prove effective in treating insulin-induced lipoatrophy [2].
Immuno Disease Comments: Mast cell stabiliser used to treat allergic conjunctivitis.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed.
Immuno Disease Comments: Phase 2 clinical trial NCT01639846 has been completed.


Show »

1. Motawi TM, Bustanji Y, El-Maraghy SA, Taha MO, Al Ghussein MA. (2013) Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J. Biochem. Mol. Toxicol., 27 (9): 425-36. [PMID:23784744]

2. Phua EJ, Lopez X, Ramus J, Goldfine AB. (2013) Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use. Diabetes Care, 36 (12): e204-5. [PMID:24265375]